Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29944074 | 1.00 | GHSR (0.71) | GHSRMAPK14HPGDALDH1A1HSD17B10 | |
| SCHEMBL29944365 | 0.89 | MAPK14 (0.63) | GHSRMAPK14HPGDALDH1A1NPC1 | |
| SCHEMBL3457123 | 0.89 | MAPK14 (0.63) | GHSRMAPK14HPGDALDH1A1NPC1 | |
| SCHEMBL2214616 | 0.89 | MAPK14 (0.63) | GHSRMAPK14HPGDALDH1A1NPC1 | |
| SCHEMBL8534513 | 0.88 | MAPK14 (0.64) | GHSRMAPK14HPGDALDH1A1NPC1 | |
| SCHEMBL30226931 | 0.88 | MAPK14 (0.64) | GHSRMAPK14HPGDALDH1A1NPC1 | |
| SCHEMBL3235960 | 0.86 | GHSR (0.67) | GHSRMAPK14HPGDALDH1A1HSD17B10 | |
| SCHEMBL17443852 | 0.86 | GHSR (0.75) | GHSRMAPK14HPGDALDH1A1HSD17B10 | |
| SCHEMBL29990457 | 0.86 | GHSR (0.67) | GHSRMAPK14HPGDALDH1A1HSD17B10 | |
| SCHEMBL31428636 | 0.85 | GHSR (0.65) | GHSRMAPK14HPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2391625-B1 | New adenosine receptor ligands and uses thereof | DOMAIN THERAPEUTICS (FR) | 2013-05-01 | — | — | EP | disclosed |
| EP-2391625-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | Domain Therapeutics (FR) | 2011-12-07 | — | — | EP | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| WO-2010084425-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2010-07-29 | — | — | WO | disclosed |
| EP-2210891-A1 | New adenosine receptor ligands and uses thereof | Domain Therapeutics (FR) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | ADORA2A, ADORA1, ADORA2B | GHSR 590/4885MAPK14 3670/4885HPGD 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.